Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID R SPIGEL

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1427074210
CMS profile
291623
Location
NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$26,969.32

67 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $16,283.31 4
Travel and Lodging $8,776.88 6
Food and Beverage $1,909.13 57

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID R SPIGEL

NPI 1427074210 · CMS profile ID 291623

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427074210?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID R SPIGEL, NPI 1427074210, CMS profile ID 291623. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427074210?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DAVID R SPIGEL, NPI 1427074210, CMS profile ID 291623. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427074210?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DAVID R SPIGEL, NPI 1427074210, CMS profile ID 291623, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1427074210?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

67 matching records · $26,969.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 67 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–67 of 67.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $26.7604/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238363569 CMS
Daiichi Sankyo Inc. $26.0204/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197056247 CMS
TerSera Therapeutics LLC $18.8804/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244055176 CMS
SpringWorks Therapeutics, Inc. $20.3604/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232171477 CMS
E.R. Squibb & Sons, L.L.C. $17.6504/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184562287 CMS
PUMA BIOTECHNOLOGY, INC. $14.9703/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251741594 CMS
Daiichi Sankyo Inc. $25.7103/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197054759 CMS
Gilead Sciences, Inc. $21.9603/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234505629 CMS
Novocure Inc. $16.0803/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251155001 CMS
AstraZeneca Pharmaceuticals LP $20.5103/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214774925 CMS
Blueprint Medicines Corporation $42.3203/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235815527 CMS
E.R. Squibb & Sons, L.L.C. $18.0502/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184562279 CMS
Novartis Pharmaceuticals Corporation $14.8202/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200575471 CMS
Stemline Therapeutics Inc. $24.1601/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244091776 CMS
Incyte Corporation $21.1001/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226071333 CMS
Astellas Pharma US Inc $25.1701/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238760614 CMS
SpringWorks Therapeutics, Inc. $21.6001/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232171470 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $59,860.23 70
PY2020 $36,690.23 22
PY2021 $8,322.17 11
PY2022 $10,977.42 15
PY2023 $19,410.79 29
PY2024 $4,614.45 49
PY2025 $26,969.32 67

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $330.27 1
PY2025 Principal investigator $2,743,094.44 294
PY2024 Recipient $8,158.57 4
PY2024 Principal investigator $2,785,077.00 438
PY2023 Recipient $284.70 2
PY2023 Principal investigator $4,850,656.80 739
PY2022 Principal investigator $6,807,992.86 678
PY2021 Recipient $4,674.69 5
PY2021 Principal investigator $4,483,626.39 542
PY2020 Recipient $9,181.02 7
PY2020 Principal investigator $3,409,148.90 303
PY2019 Recipient $17,882.16 3
PY2019 Principal investigator $4,461,096.48 304

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

295 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $71,685.84 12/31/2025 Non-covered Recipient Entity
Tennessee Oncology, PLLC
A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1232931302
Principal investigator 1 Merck Sharp & Dohme LLC $248,671.08 12/31/2025 Non-covered Recipient Entity
Tennessee Oncology, PLLC
A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1232931304
Principal investigator 1 Merck Sharp & Dohme LLC $76,118.93 12/31/2025 Non-covered Recipient Entity
Tennessee Oncology
A Phase 1, Dose-Escalation and Expansion Trial of PT2977, A HIF-2a Inhibitor, In Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1232931582
Principal investigator 1 Merck Sharp & Dohme LLC $808,180.68 12/31/2025 Non-covered Recipient Entity
Tennessee Oncology
A Phase 1, Dose-Escalation and Expansion Trial of PT2977, A HIF-2a Inhibitor, In Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1232931756
Principal investigator 1 Merck Sharp & Dohme LLC $1,221.75 12/31/2025 Non-covered Recipient Entity
Sarah Cannon Cancer Institute Nashville
A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1232935819
Principal investigator 1 AstraZeneca Pharmaceuticals LP $800.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer No dispute reported 06/30/2026 1185553992
Principal investigator 1 Janssen Research & Development, LLC $2,248.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175323782
Principal investigator 1 ModernaTX, Inc. $2,500.00 12/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252996899
Principal investigator 1 ModernaTX, Inc. $1,000.00 12/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252996901
Principal investigator 1 Nuvation Bio Inc. $2,500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC No dispute reported 06/30/2026 1206087161
Principal investigator 1 Ascendis Pharma Endocrinology Inc $25,010.94 12/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
IL Believe No dispute reported 06/30/2026 1233998022
Principal investigator 1 Ascendis Pharma Endocrinology Inc $3,493.01 12/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
IL Believe No dispute reported 06/30/2026 1233998026
Principal investigator 1 Merck Sharp & Dohme LLC $20,741.00 12/10/2025 Non-covered Recipient Entity
Tennessee Oncology, PLLC
A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1232931300
Principal investigator 1 Nuvation Bio Inc. $2,500.00 12/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC No dispute reported 06/30/2026 1206087159
Principal investigator 1 Genentech, Inc. $95.00 12/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC No dispute reported 06/30/2026 1211649275
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $112.00 12/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 1, Open-Label, Dose Finding Study of CC-95251, A Monoclonal Antibody Directed Against SIRPa, Alone and in Combination with Cetuximab or Rituximab in Subjects with Advanced Solid and Hematologic Cancers No dispute reported 06/30/2026 1235993817
Principal investigator 1 ModernaTX, Inc. $5,000.00 11/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252996909
Principal investigator 1 GlaxoSmithKline, LLC. $930.00 11/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192143371
Principal investigator 1 Janssen Research & Development, LLC $455.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175325575
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $5,078.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649528
Principal investigator 1 Janssen Research & Development, LLC $400.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175319211
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,000.00 10/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649519
Principal investigator 1 Servier BioInnovation $624.00 10/27/2025 Non-covered Recipient Entity
WCG IRB
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235978143
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,000.00 10/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649515
Principal investigator 1 Janssen Research & Development, LLC $273.00 10/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175321981
Principal investigator 1 Janssen Research & Development, LLC $1,006.00 10/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175324863
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $4,086.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649522
Principal investigator 1 Ascendis Pharma Endocrinology Inc $650.00 10/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
IL Believe No dispute reported 06/30/2026 1233997149
Principal investigator 1 GlaxoSmithKline, LLC. $650.00 09/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192147707
Principal investigator 1 Janssen Research & Development, LLC $29.00 09/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175319403
Principal investigator 1 Janssen Research & Development, LLC $1,400.00 09/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175323771
Principal investigator 1 BioNTech SE $2,500.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT-122-01 No dispute reported 06/30/2026 1249019444
Principal investigator 1 BioNTech SE $2,000.00 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT-122-01 No dispute reported 06/30/2026 1249019446
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,000.00 09/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649420
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $151.80 09/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649431
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 09/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Taiho Phase 1 Study of TAS2940 in Solid Tumors with EGFR and/or HER2 Aberrations [TAS2940-101] - [12TAI2001714] No dispute reported 06/30/2026 1211415501
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 09/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Taiho Phase 1 Study of TAS2940 in Solid Tumors with EGFR and/or HER2 Aberrations [TAS2940-101] - [12TAI2001714] No dispute reported 06/30/2026 1211416212
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 09/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Taiho Phase 1 Study of TAS2940 in Solid Tumors with EGFR and/or HER2 Aberrations [TAS2940-101] - [12TAI2001714] No dispute reported 06/30/2026 1211416214
Principal investigator 1 Genentech, Inc. $21,440.00 09/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC No dispute reported 06/30/2026 1211649265
Principal investigator 1 Genentech, Inc. $2,400.00 09/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC No dispute reported 06/30/2026 1211649268
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $2,090.00 09/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649402
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 09/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649449
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,500.00 09/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649460
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,000.00 09/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649506
Principal investigator 1 Ascendis Pharma Endocrinology Inc $1,167.60 09/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
IL Believe No dispute reported 06/30/2026 1233996731
Principal investigator 1 Astellas Pharma Global Development $183.67 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185834
Principal investigator 1 Janssen Research & Development, LLC $600.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175319246
Principal investigator 1 Janssen Research & Development, LLC $29.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175319520
Principal investigator 1 Janssen Research & Development, LLC $29.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175319801
Principal investigator 1 Janssen Research & Development, LLC $29.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175319966
Principal investigator 1 Janssen Research & Development, LLC $29.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175322983
Principal investigator 1 Janssen Research & Development, LLC $635.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175323425
Principal investigator 1 Janssen Research & Development, LLC $29.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175323970
Principal investigator 1 Janssen Research & Development, LLC $29.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175324327
Principal investigator 1 Janssen Research & Development, LLC $29.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175324594
Principal investigator 1 Janssen Research & Development, LLC $29.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175325091
Principal investigator 1 Janssen Research & Development, LLC $29.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175326118
Principal investigator 1 Astellas Pharma Global Development $500.00 08/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185822
Principal investigator 1 Astellas Pharma Global Development $500.00 08/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185824
Principal investigator 1 Astellas Pharma Global Development $500.00 08/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185826
Principal investigator 1 Astellas Pharma Global Development $500.00 08/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185828
Principal investigator 1 Astellas Pharma Global Development $500.00 08/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185830
Principal investigator 1 Astellas Pharma Global Development $500.00 08/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185832
Principal investigator 1 Genentech, Inc. $900.00 08/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211652023
Principal investigator 1 Servier BioInnovation $400.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235973890
Principal investigator 1 Servier BioInnovation $2,500.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235973893
Principal investigator 1 Servier BioInnovation $296.04 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235973898
Principal investigator 1 Servier BioInnovation $1,000.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235973902
Principal investigator 1 Servier BioInnovation $1,000.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235973907
Principal investigator 1 Janssen Research & Development, LLC $91.00 08/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175323855
Principal investigator 1 BioNTech SE $2,500.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT-122-01 No dispute reported 06/30/2026 1249019442
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 08/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649414
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 08/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649418
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 08/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649426
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 08/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649456
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 08/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649481
Principal investigator 1 Ascendis Pharma Endocrinology Inc $404.28 08/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
IL Believe No dispute reported 06/30/2026 1233996643
Principal investigator 1 Merck Sharp & Dohme LLC $10,620.00 08/11/2025 Non-covered Recipient Entity
Tennessee Oncology
A Phase 1, Dose-Escalation and Expansion Trial of PT2977, A HIF-2a Inhibitor, In Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1232931580
Principal investigator 1 GlaxoSmithKline, LLC. $1,090.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192143380
Principal investigator 1 ModernaTX, Inc. $450.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252996897
Principal investigator 1 Incyte Corporation $300.00 08/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240585227
Principal investigator 1 Amgen Inc. $19,728.25 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTION LLC
A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation No dispute reported 06/30/2026 1246647978
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649406
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649410
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649435
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649440
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649444
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649464
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649468
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649489
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649500
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649503
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $175.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649511
Principal investigator 1 Astellas Pharma Global Development $1,208.50 07/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185820
Principal investigator 1 Novocure Inc. $500.00 07/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LL
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856469
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,000.00 07/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649399
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,000.00 07/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649424
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,500.00 07/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649472
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,000.00 07/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649476
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $2,719.00 07/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649485
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,060.00 07/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649493
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,000.00 07/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649497
Principal investigator 1 ModernaTX, Inc. $5,000.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252996913
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,722.50 07/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-Line Therapy in Metastatic Microsatellite-Stable Colorectal Cancer (COLUMBIA 1) No dispute reported 06/30/2026 1185553982
Principal investigator 1 Genentech, Inc. $607.50 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211652039
Principal investigator 1 Blueprint Medicines Corporation $6,668.00 07/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
BLU-945-1101 No dispute reported 06/30/2026 1235784956
Principal investigator 1 Genentech, Inc. $35,524.71 07/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211652002
Principal investigator 1 Ascendis Pharma Endocrinology Inc $650.00 07/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
IL Believe No dispute reported 06/30/2026 1233996547
Principal investigator 1 GlaxoSmithKline, LLC. $650.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192133714
Principal investigator 1 Janssen Research & Development, LLC $273.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175320998
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,400.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Durvalumab or Placebo in Combination With Gemcitabine Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer TOPAZ-1 No dispute reported 06/30/2026 1185553998
Principal investigator 1 GlaxoSmithKline, LLC. $91.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192143363
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,713.00 07/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage Non Small Cell Lung Cancer No dispute reported 06/30/2026 1235993801
Principal investigator 1 Janssen Research & Development, LLC $281.00 07/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175321703
Principal investigator 1 BioNTech SE $2,500.00 07/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT-122-01 No dispute reported 06/30/2026 1249019448
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 06/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175320466
Principal investigator 1 Amgen Inc. $30,192.50 06/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTION LLC
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression No dispute reported 06/30/2026 1246647936
Principal investigator 1 Novocure Inc. $1,000.00 06/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LL
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856311
Principal investigator 1 Novocure Inc. $1,200.00 06/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LL
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856651
Principal investigator 1 Servier BioInnovation $2,304.00 06/25/2025 Non-covered Recipient Entity
WCG IRB
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235978137
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $450.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Cancer Center
A Phase 1/2, Openlabel Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1235993995
Principal investigator 1 Servier BioInnovation $1,270.96 06/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235973881
Principal investigator 1 Blueprint Medicines Corporation $472.00 06/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
BLU-945-1101 No dispute reported 06/30/2026 1235784952
Principal investigator 1 Servier BioInnovation $3,909.00 06/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235973886
Principal investigator 1 Genentech, Inc. $227.25 06/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211651546
Principal investigator 1 Genentech, Inc. $3,223.76 06/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211651567
Principal investigator 1 BioNTech SE $2,500.00 06/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT-122-01 No dispute reported 06/30/2026 1249019612
Principal investigator 1 Genentech, Inc. $3,621.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649627
Principal investigator 1 Genentech, Inc. $2,666.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649640
Principal investigator 1 Genentech, Inc. $3,290.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649699
Principal investigator 1 Genentech, Inc. $4,082.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649701
Principal investigator 1 Genentech, Inc. $3,290.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649762
Principal investigator 1 Genentech, Inc. $2,185.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649786
Principal investigator 1 Genentech, Inc. $5,915.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649792
Principal investigator 1 Incyte Corporation $2,000.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240585210
Principal investigator 1 Incyte Corporation $2,000.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240585214
Principal investigator 1 Ipsen Bioscience Inc. $525.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON CANCER INSTITUTE AT HDH
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176545069
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,125.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211415503
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211415505
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,412.26 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211416222
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211416224
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211416226
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211416916
Principal investigator 1 TAIHO ONCOLOGY, INC. $4,000.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211416918
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,690.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211417607
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211418327
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211418329
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211418331
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211419739
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,940.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211419741
Principal investigator 1 TAIHO ONCOLOGY, INC. $7,500.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211419743
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211419745
Principal investigator 1 TAIHO ONCOLOGY, INC. $624.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211420467
Principal investigator 1 TAIHO ONCOLOGY, INC. $519.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211420469
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211420471
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,125.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211420473
Principal investigator 1 Ascendis Pharma Endocrinology Inc $606.42 06/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
IL Believe No dispute reported 06/30/2026 1233995875
Principal investigator 1 GlaxoSmithKline, LLC. $370.00 06/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192147711
Principal investigator 1 Astellas Pharma Global Development $334.00 05/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185818
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,833.95 05/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC) (MATTERHORN) No dispute reported 06/30/2026 1185553990
Principal investigator 1 BioNTech SE $2,500.00 05/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT-122-01 No dispute reported 06/30/2026 1249019608
Principal investigator 1 BeiGene, Ltd. $84.20 05/19/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190320788
Principal investigator 1 Ascendis Pharma Endocrinology Inc $1,747.46 05/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
IL Believe No dispute reported 06/30/2026 1233995647
Principal investigator 1 Janssen Research & Development, LLC $1,696.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175326422
Principal investigator 1 Janssen Research & Development, LLC $182.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175326618
Principal investigator 1 Incyte Corporation $2,000.00 05/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240585197
Principal investigator 1 Incyte Corporation $2,000.00 05/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240585202
Principal investigator 1 Incyte Corporation $2,000.00 05/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240585219
Principal investigator 1 Incyte Corporation $2,000.00 05/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240585223
Principal investigator 1 Incyte Corporation $1,000.00 05/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240585192
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $58,493.34 05/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220816796
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,175.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors No dispute reported 06/30/2026 1220796635
Principal investigator 1 Genentech, Inc. $8,550.00 05/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211650913
Principal investigator 1 Genentech, Inc. $2,750.00 05/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211651477
Principal investigator 1 BioNTech SE $337.50 05/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT-122-01 No dispute reported 06/30/2026 1249019586
Principal investigator 1 BioNTech SE $2,500.00 05/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT-122-01 No dispute reported 06/30/2026 1249019600
Principal investigator 1 ModernaTX, Inc. $2,500.00 05/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252996911
Principal investigator 1 Genentech, Inc. $4,359.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649673
Principal investigator 1 Genentech, Inc. $3,888.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649694
Principal investigator 1 Genentech, Inc. $2,571.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649710
Principal investigator 1 Genentech, Inc. $3,836.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649728
Principal investigator 1 Genentech, Inc. $7,950.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649779
Principal investigator 1 Genentech, Inc. $15,100.00 05/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211650892
Principal investigator 1 Genentech, Inc. $12,100.00 05/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211651052
Principal investigator 1 Genentech, Inc. $14,100.00 05/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211651106
Principal investigator 1 Genentech, Inc. $4,350.00 05/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211651331
Principal investigator 1 Genentech, Inc. $4,050.00 05/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211651461
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211416216
Principal investigator 1 TAIHO ONCOLOGY, INC. $3,858.00 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211416218
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211416220
Principal investigator 1 TAIHO ONCOLOGY, INC. $490.00 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211416908
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211416910
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211416912
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,000.00 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211416914
Principal investigator 1 TAIHO ONCOLOGY, INC. $3,421.93 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211417603
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211417605
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211418323
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211418325
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,500.00 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS-2940 No dispute reported 06/30/2026 1211419737
Principal investigator 1 SANOFI US SERVICES INC. $7,112.00 04/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies No dispute reported 06/30/2026 1226082002
Principal investigator 1 AstraZeneca UK Limited $1,600.00 04/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2) No dispute reported 06/30/2026 1185553988
Principal investigator 1 Janssen Research & Development, LLC $91.00 04/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175321305
Principal investigator 1 GlaxoSmithKline, LLC. $182.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192133703
Principal investigator 1 GlaxoSmithKline, LLC. $273.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192133708
Principal investigator 1 GlaxoSmithKline, LLC. $182.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192143367
Principal investigator 1 GlaxoSmithKline, LLC. $3,640.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192143376
Principal investigator 1 GlaxoSmithKline, LLC. $91.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192143389
Principal investigator 1 GlaxoSmithKline, LLC. $364.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192143393
Principal investigator 1 GlaxoSmithKline, LLC. $819.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192147697
Principal investigator 1 GlaxoSmithKline, LLC. $364.00 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192147702
Principal investigator 1 ModernaTX, Inc. $1,500.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252996893
Principal investigator 1 ModernaTX, Inc. $1,100.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252996907
Principal investigator 1 ModernaTX, Inc. $2,500.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252996915
Principal investigator 1 Incyte Corporation $3,200.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240585206
Principal investigator 1 Genentech, Inc. $6,344.00 04/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph Ia SAD of aLy6G6D in colorectal cancer CRC No dispute reported 06/30/2026 1211651243
Principal investigator 1 Ipsen Bioscience Inc. $7,900.65 04/01/2025 Non-covered Recipient Entity
SARAH CANNON CANCER INSTITUTE AT HDH
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176545047
Principal investigator 1 Merck Sharp & Dohme LLC $157,600.00 04/01/2025 Non-covered Recipient Entity
Tennessee Oncology, PLLC SCRI
An Open-Label Phase 1a,1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1232932643
Principal investigator 1 Boehringer Ingelheim International GmbH $134.38 03/31/2025 Non-covered Recipient Entity
Scri Oncology Partners
Phase 1 dose escalation study of BI 765049 mono / combi No dispute reported 06/30/2026 1220767681
Principal investigator 1 Boehringer Ingelheim International GmbH $134.38 03/31/2025 Non-covered Recipient Entity
Scri Oncology Partners
Phase 1 dose escalation study of BI 765049 mono / combi No dispute reported 06/30/2026 1220767683
Principal investigator 1 Boehringer Ingelheim International GmbH $134.38 03/31/2025 Non-covered Recipient Entity
Scri Oncology Partners
Phase 1 dose escalation study of BI 765049 mono / combi No dispute reported 06/30/2026 1220767685
Recipient F. Hoffmann-La Roche AG $330.27 03/31/2025 Covered Recipient Physician PH III OPEN LABEL STDY ATEZO VS PLATINUM PEMETREXED GEMCITABINE FOR PDL1 CHEMO NAIVE STG IV NSCLC No dispute reported 06/30/2026 1211535338
Principal investigator 1 GlaxoSmithKline, LLC. $650.00 03/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192143385
Principal investigator 1 Astellas Pharma Global Development $250.00 03/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185812
Principal investigator 1 Astellas Pharma Global Development $500.00 03/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185814
Principal investigator 1 Astellas Pharma Global Development $588.00 03/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234185816
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,861.75 03/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Durvalumab or Placebo in Combination With Gemcitabine Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer TOPAZ-1 No dispute reported 06/30/2026 1185553994
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $300.00 03/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors No dispute reported 06/30/2026 1220796631
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $650.00 03/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors No dispute reported 06/30/2026 1220796633
Principal investigator 1 Genentech, Inc. $2,021.00 03/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211650497
Principal investigator 1 Novocure GmbH $500.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LL
EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma No dispute reported 06/30/2026 1250867335
Principal investigator 1 Novocure GmbH $1,200.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LL
EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma No dispute reported 06/30/2026 1250867337
Principal investigator 1 Novocure GmbH $1,000.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LL
EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma No dispute reported 06/30/2026 1250868284
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $38,487.00 03/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence No dispute reported 06/30/2026 1235993807
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28,864.64 03/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors No dispute reported 06/30/2026 1220816736
Principal investigator 1 Incyte Corporation $2,000.00 03/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240585187
Principal investigator 1 Janssen Research & Development, LLC $91.00 03/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LL C
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175320139
Principal investigator 1 BioNTech SE $2,500.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT-122-01 No dispute reported 06/30/2026 1249019402
Principal investigator 1 BioNTech SE $2,500.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT-122-01 No dispute reported 06/30/2026 1249019733
Principal investigator 1 Servier BioInnovation $2,066.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235973870
Principal investigator 1 Servier BioInnovation $1,456.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235973876
Principal investigator 1 Genentech, Inc. $1,350.00 03/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC No dispute reported 06/30/2026 1211649260
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $23,065.00 03/10/2025 Non-covered Recipient Entity
Tennessee Oncology, PLLC
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9ER No dispute reported 06/30/2026 1235993337
Principal investigator 1 Genentech, Inc. $1,440.00 03/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph Ia SAD of aLy6G6D in colorectal cancer CRC No dispute reported 06/30/2026 1211650804
Principal investigator 1 ModernaTX, Inc. $2,500.00 02/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252996905
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,000.00 02/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649383
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $880.00 02/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649387
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,537.00 02/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649396
Principal investigator 1 ModernaTX, Inc. $2,500.00 02/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252996903
Principal investigator 1 TAIHO ONCOLOGY, INC. $38,173.74 02/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
TAS2940-101 No dispute reported 06/30/2026 1211415499
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,699.00 02/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 1235993815
Principal investigator 1 ModernaTX, Inc. $10,825.00 02/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252996917
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,239.33 02/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer No dispute reported 06/30/2026 1235993805
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $30,743.00 02/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Randomized, Multicenter, Double-Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal or Gastroesophageal Junction Cancer No dispute reported 06/30/2026 1235993809
Principal investigator 1 BioNTech SE $675.00 02/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT-122-01 No dispute reported 06/30/2026 1249019721
Principal investigator 1 Boehringer Ingelheim International GmbH $134.38 01/31/2025 Non-covered Recipient Entity
Scri Oncology Partners
Phase 1 dose escalation study of BI 765049 mono / combi No dispute reported 06/30/2026 1220767675
Principal investigator 1 Boehringer Ingelheim International GmbH $134.38 01/31/2025 Non-covered Recipient Entity
Scri Oncology Partners
Phase 1 dose escalation study of BI 765049 mono / combi No dispute reported 06/30/2026 1220767677
Principal investigator 1 Boehringer Ingelheim International GmbH $134.38 01/31/2025 Non-covered Recipient Entity
Scri Oncology Partners
Phase 1 dose escalation study of BI 765049 mono / combi No dispute reported 06/30/2026 1220767679
Principal investigator 1 Amgen Inc. $1,290.00 01/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation No dispute reported 06/30/2026 1246647830
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $300.00 01/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors No dispute reported 06/30/2026 1220796629
Principal investigator 1 SANOFI US SERVICES INC. $6,082.00 01/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Inst Llc
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies No dispute reported 06/30/2026 1226084940
Principal investigator 1 SANOFI US SERVICES INC. $90.00 01/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Inst Llc
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies No dispute reported 06/30/2026 1226084944
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,496.56 01/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies No dispute reported 06/30/2026 1235993803
Principal investigator 1 Genentech, Inc. $3,050.00 01/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211650618
Principal investigator 1 ModernaTX, Inc. $2,500.00 01/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252996895
Principal investigator 1 Novocure GmbH $238.33 01/22/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LL
EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma No dispute reported 06/30/2026 1250867439
Principal investigator 1 Eisai Inc. $56.00 01/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560730
Principal investigator 1 Eisai Inc. $56.00 01/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560734
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,000.00 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1211649391
Principal investigator 1 Servier BioInnovation $1,456.00 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235973851
Principal investigator 1 Servier BioInnovation $2,066.00 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235973856
Principal investigator 1 Servier BioInnovation $1,456.00 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235973861
Principal investigator 1 Servier BioInnovation $1,456.00 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235973865
Principal investigator 1 Eisai Inc. $125.00 01/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560728
Principal investigator 1 Eisai Inc. $125.00 01/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560732
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $832.00 01/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 1/2, Openlabel Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1235993811
Principal investigator 1 Eli Lilly and Company $11,197.50 01/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 1/2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING RET FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER, AND OTHER TUMORS WITH RET ACTIVATION (LIBRETTO-001) No dispute reported 06/30/2026 1187887824
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,567.00 01/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer No dispute reported 06/30/2026 1185553986
Principal investigator 1 BioNTech SE $2,500.00 01/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT-122-01 No dispute reported 06/30/2026 1249019725
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,040.00 01/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy ADRIATIC No dispute reported 06/30/2026 1185553984
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,460.00 01/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors No dispute reported 06/30/2026 1220796627
Principal investigator 1 AstraZeneca UK Limited $380,993.25 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase 1 Open label Dose escalation and Dose expansion study to evaluate the safety to evaluate the safety tolerability Pharmacokinetics Immunogenicity and Antitumor activity of MEDI5752 in subjects with advanced solid tumors No dispute reported 06/30/2026 1185553980
Principal investigator 1 Genentech, Inc. $2,750.00 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211650327
Principal investigator 1 Genentech, Inc. $349.00 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211650571
Principal investigator 1 Genentech, Inc. $3,500.00 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211650752
Principal investigator 1 Genentech, Inc. $12,650.00 01/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211650824
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,355.00 01/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) No dispute reported 06/30/2026 1235993813
Principal investigator 1 Incyte Corporation $2,000.00 01/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240585183
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,012.62 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC) (MATTERHORN) No dispute reported 06/30/2026 1185553996
Principal investigator 1 Genentech, Inc. $400.00 01/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211650283
Principal investigator 1 Genentech, Inc. $4,000.00 01/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211650305
Principal investigator 1 Genentech, Inc. $13,550.00 01/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211650357
Principal investigator 1 Genentech, Inc. $2,850.00 01/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211650417
Principal investigator 1 Genentech, Inc. $2,000.00 01/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211650800
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30.09 01/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors No dispute reported 06/30/2026 1220814281
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30.09 01/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors No dispute reported 06/30/2026 1220814283